Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack Lee

Showing results (561-570 of 594) with videos related to

Pageof 60
Sort By:
Cancer Discovery|July 23, 2017
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical RecurrenceAlexandre Reuben, Rachel Gittelman, Jianjun Gao, et al.
Nature Communications|April 11, 2024
Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insightsSheeba J Sujit, Muhammad Aminu, Tatiana V Karpinets, et al.
Journal for Immunotherapy of Cancer|August 11, 2021
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancerMarcelo V Negrao, Ferdinandos Skoulidis, Meagan Montesion, et al.
Nature Communications|May 12, 2021
Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular featuresHitoshi Dejima, Xin Hu, Runzhe Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 24, 2012
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistanceLauren Averett Byers, Lixia Diao, Jing Wang, et al.
Nature Communications|February 8, 2023
Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancerLingzhi Hong, Muhammad Aminu, Shenduo Li, et al.
Cell Reports. Medicine|March 12, 2024
Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of conceptMorteza Salehjahromi, Tatiana V Karpinets, Sheeba J Sujit, et al.
Nature Communications|July 24, 2025
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLCMaliazurina B Saad, Qasem Al-Tashi, Lingzhi Hong, et al.
Nature Communications|April 5, 2022
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancersOmar Alhalabi, Jianfeng Chen, Yuxue Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 2, 2026
Machine learning assessment of pathologic response in lung cancer resections after neoadjuvant therapy - IASLC MPR ProjectSanja Dacic, Daniel Shenker, Mary Redman, et al.
Pageof 60

Showing results (561-570 of 594) with videos related to

Sort By:
Pageof 60
Cancer Discovery|July 23, 2017
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical RecurrenceAlexandre Reuben, Rachel Gittelman, Jianjun Gao, et al.
Nature Communications|April 11, 2024
Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insightsSheeba J Sujit, Muhammad Aminu, Tatiana V Karpinets, et al.
Journal for Immunotherapy of Cancer|August 11, 2021
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancerMarcelo V Negrao, Ferdinandos Skoulidis, Meagan Montesion, et al.
Nature Communications|May 12, 2021
Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular featuresHitoshi Dejima, Xin Hu, Runzhe Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 24, 2012
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistanceLauren Averett Byers, Lixia Diao, Jing Wang, et al.
Nature Communications|February 8, 2023
Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancerLingzhi Hong, Muhammad Aminu, Shenduo Li, et al.
Cell Reports. Medicine|March 12, 2024
Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of conceptMorteza Salehjahromi, Tatiana V Karpinets, Sheeba J Sujit, et al.
Nature Communications|July 24, 2025
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLCMaliazurina B Saad, Qasem Al-Tashi, Lingzhi Hong, et al.
Nature Communications|April 5, 2022
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancersOmar Alhalabi, Jianfeng Chen, Yuxue Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 2, 2026
Machine learning assessment of pathologic response in lung cancer resections after neoadjuvant therapy - IASLC MPR ProjectSanja Dacic, Daniel Shenker, Mary Redman, et al.
Pageof 60